ACT - アカシア・リサ―チ (AdvisorShares Vice ETF) アカシア・リサ―チ

 ACTのチャート


 ACTの企業情報

symbol ACT
会社名 Acacia Research Corp (アカシア・リサ―チ)
分野(sector)   
産業(industry)   
業種    金融(Financials)
概要 事業概要 --   アカシア・リサ―チは米国の特許取得・ライセンス企業。主に特許権の取得、ライセンス供与・維持・管理に従事する。特許者の特許出願、保護、ライセンス供与、訴訟を支援。また、経営不振企業やベンチャ―企業とパ―トナ―となり、特許を取得するほか、米国内外の特許権を買い取る。181件の特許権を所有、管理する。本社はカリフォルニア州。   
本社所在地 520 Newport Center Drive 12th Floor Newport Beach CA 92660 USA
代表者氏名
代表者役職名
電話番号
設立年月日 33970
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 13人
url www.acaciaresearch.com
nasdaq_url https://www.nasdaq.com/symbol/act
adr_tso
EBITDA EBITDA ー
終値(lastsale) 27.0698
時価総額(marketcap) 14888390
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ACTのテクニカル分析


 ACTのニュース

   Global Transdermal Skin Patches Market 2020-2030 - Featuring Profiles of Mylan Pharma, Hisamitsu Pharma, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan, Actavis, Mundipharma, and More  2020/06/19 11:30:00 PR Newswire
DUBLIN, June 19, 2020 /PRNewswire/ -- The "Transdermal Skin Patches Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering. The global transdermal skin patches market was worth $6.23 billion in 2019. It is expected to grow at a compound annual growth rate…
   YOLO Portfolio Manager For AdvisorShares Explains Why Not All Cannabis ETFs Are Created Equal  2020/06/16 15:40:49 Benzinga Feeds
This special presentation from AdvisorShares comes from Benzinga’s Virtual Cannabis Capital Conference that took place on June 1. Click here for more coverage of this event with presentations from some of the top CEOs, investors and lenders in the cannabis space. When looking at which ETFs to invest in, Dan Ahrens, portfolio manager of the first and only cannabis ETF with U.S. MSO exposure, cautions that “not all cannabis ETFs are created equal.” Being bullish on the cannabis industry, the firm launched two cannabis-focused ETFs: a blended approach in the AdvisorShares Vice ETF (NASDAQ: ACT ) and a pure-play approach in the AdvisorShares Pure Cannabis ETF (NYSE: YOLO ). AdvisorShares is an investment management firm based in Bethesda, Maryland that offers a variety of actively managed equity and fixed income ETFs. The ETF YOLO is the first actively managed ETF to deliver … Full story available on Benzinga.com
   IP : Actual Experience plc - Interim Results | MarketScreener  2020/06/08 09:42:07 MarketScreener
UNAUDITED CONSOLIDATED INTERIM RESULTS for the six months ended 31 March 2020 Actual Experience plc , the analytics-as-a-service company, is pleased to announce… | June 8, 2020
   US Dermatophytic Onychomycosis Drug Forecast and Market Analysis 2020-2028, Featuring Actavis, Allergan and Topica Pharmaceuticals  2020/05/21 15:00:00 PR Newswire
DUBLIN, May 21, 2020 /PRNewswire/ -- The "Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering. Sales of drugs in the US DO market were approximately $208.8M in 2018, not taking into account over-the-counter…
   Here's How Much Investing $100 In Allergan Stock Back In 2010 Would Be Worth Today  2020/02/10 16:48:12 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Allergan’s Big Decade One stock that had plenty of highs and lows over the past decade is pharmaceutical giant Allergan plc (NYSE: AGN ). Allergan’s decade was defined by blockbuster deals and failed deals. Today’s Allergan actually started the 2010s as Irish company Actavis. In 2015, Actavis acquired Allergan and re-domiciled it in Ireland as part of a tax inversion deal that helped Allergan avoid paying U.S. taxes. As part of the deal, Actavis took over Allergan’s name. Actavis was subsequently blocked by the U.S. Treasury in 2016 from … Full story available on Benzinga.com
   Here's How Much Investing $100 In Allergan Stock Back In 2010 Would Be Worth Today  2020/02/10 16:48:12 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Allergan’s Big Decade One stock that had plenty of highs and lows over the past decade is pharmaceutical giant Allergan plc (NYSE: AGN ). Allergan’s decade was defined by blockbuster deals and failed deals. Today’s Allergan actually started the 2010s as Irish company Actavis. In 2015, Actavis acquired Allergan and re-domiciled it in Ireland as part of a tax inversion deal that helped Allergan avoid paying U.S. taxes. As part of the deal, Actavis took over Allergan’s name. Actavis was subsequently blocked by the U.S. Treasury in 2016 from … Full story available on Benzinga.com
   IP : Actual Experience plc - Board Changes | MarketScreener  2019/12/04 12:19:15 MarketScreener
Actual Experience plc , the analytics-as-a-service company, is pleased to announce the following changes to its Board. Kirsten English will join the Board as… | December 4, 2019
   Actual Experience : Board Changes | MarketScreener  2019/12/04 07:28:18 MarketScreener
4 December 2019 Actual Experience plc Board Changes Actual Experience plc , the analytics-as-a-service… | December 4, 2019
   RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer  2019/05/28 11:00:00 Benzinga
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (Tel-Aviv Stock Exchange: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company's commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia ® (RHB-105) 1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019. In addition, Dr. Almenoff will oversee the clinical development of RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections and the pivotal Phase 3 study planned to be initiated in the second half of 2019. With over 20 years of experience in the pharmaceutical industry, Dr.
   IP : Actual Experience plc - Board Changes | MarketScreener  2019/12/04 12:19:15 MarketScreener
Actual Experience plc , the analytics-as-a-service company, is pleased to announce the following changes to its Board. Kirsten English will join the Board as… | December 4, 2019
   Actual Experience : Board Changes | MarketScreener  2019/12/04 07:28:18 MarketScreener
4 December 2019 Actual Experience plc Board Changes Actual Experience plc , the analytics-as-a-service… | December 4, 2019
   RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer  2019/05/28 11:00:00 Benzinga
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (Tel-Aviv Stock Exchange: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company's commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia ® (RHB-105) 1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019. In addition, Dr. Almenoff will oversee the clinical development of RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections and the pivotal Phase 3 study planned to be initiated in the second half of 2019. With over 20 years of experience in the pharmaceutical industry, Dr.

 関連キーワード  (― 米国株 アカシア・リサ―チ ACT AdvisorShares Vice ETF)

 twitter  (公式ツイッターやCEOツイッターなど)